Detection of Serum Antibodies to S‐Antigen by Surface Plasmon Resonance (SPR)

Kurowska, Ewa; Szymiczek, Magdalena; Gorczyca, Wojciech; Kuropatwa, Marianna

doi:10.1080/15321810600862140

Cited by 6 publications

(4 citation statements)

References 15 publications

(6 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The technology's breadth of applications is further illustrated by the range of articles investigating oligonucleotides , small molecules , carbohydrates , and extracellular matrix components . In addition, the number of articles describing biosensor work in clinical support [1008][1009][1010][1011][1012][1013][1014][1015][1016][1017][1018][1019][1020][1021][1022][1023][1024], food/agricultural/veterinary/environmental sciences [1025][1026][1027][1028][1029][1030][1031][1032][1033][1034][1035][1036][1037][1038], and membrane/virus/cell characterization [1039][1040][1041][1042][1043][1044][1045][1046][1047][1048][1049][1050] demonstrate Biacore's emerging contributions in these fields. Biacore's more unusual applications, including the characterization of fibrils and the analysis of crude analytes are summarized in References 1051-1066.…”

Section: Methodsmentioning

confidence: 99%

Survey of the year 2006 commercial optical biosensor literature

Rich

Myszka

2007

J of Molecular Recognition

108

View full text Add to dashboard Cite

We identified 1219 articles published in 2006 that described work performed using commercial optical biosensor platforms. It is interesting to witness how the biosensor market is maturing with an increased number of instrument manufacturers offering a wider variety of platforms. However, it is clear from a review of the results presented that the advances in technology are outpacing the skill level of the average biosensor user. While we can track a gradual improvement in the quality of the published work, we clearly have a long way to go before we capitalize on the full potential of biosensor technology. To illustrate what is right with the biosensor literature, we highlight the work of 10 groups who have their eye on the ball. To help out the rest of us who have the lights on but nobody home, we use the literature to address common myths about biosensor technology.

show abstract

Section: Methodsmentioning

confidence: 99%

Survey of the year 2006 commercial optical biosensor literature

Rich

Myszka

2007

J of Molecular Recognition

108

View full text Add to dashboard Cite

show abstract

“…The SPR has been used extensively to study antigen/antibody interactions and measure their binding kinetics 50,51 . In majority of diagnostic interventions, this technique has been utilized to detect presence of antibodies in serum using an immobilized antigen ligand on the chip 52 . SPR assays has been reported for detecting protein biomarkers in human sera in cases of pancreatic cancer 46 , ovarian cancer 49 and coronary artery disease 24 .…”

Section: Discussionmentioning

confidence: 99%

Surface plasmon resonance immunosensor for label-free detection of BIRC5 biomarker in spontaneously occurring canine mammary tumours

Jena

Shrivastava

Saxena

et al. 2019

Sci Rep

View full text Add to dashboard Cite

We report detection of Baculoviral inhibitor of apoptosis repeat containing-5 (BIRC5) protein biomarker in dog serum by label-free surface plasmon resonance (SPR) immunosensor. Initially, overexpression of BIRC5 in canine mammary tumour (CMT) tissues was confirmed by real-time PCR. Recombinant BIRC5 was produced and protein specific antibodies developed in guinea pig specifically reacted with native protein in immunohistochemistry and immunocytochemistry. SPR immunosensor was developed by fabricating anti-BIRC5 antibodies on gold sensor disc. The equilibrium dissociation constant, (KD = kd/ka) was 12.1 × 10−12 M; which indicates that antibodies are of high affinity with sensitivity in picomolar range. The SPR assay could detect as low as 6.25 pg/ml of BIRC5 protein in a calibration experiment (r2 = 0.9964). On testing real clinical samples, 95% specificity and 73.33% sensitivity were recorded. The average amount of serum BIRC5 in dogs with CMT was 110.02 ± 9.77 pg/ml; whereas, in non-cancerous disease conditions, 44.79 ± 4.28 pg/ml and in healthy dog sera 30.28 ± 2.99 pg/ml protein was detected. The SPR immunosensor for detection of BIRC5 in dog sera is reported for the first time and this may find prognostic and diagnostic applications in management of CMT. In future, ‘on-site’ sensors can be developed using this technique for near-patient testing.

show abstract

“…Very few studies have measured biomarkers in blood samples using SPR biosensors. [15][16][17][18][19] An in situ filter consisting of micro slit arrays was fabricated on the gold surface of an SPR device for on-chip blood cell filtration and biomarker detection in one step. 20 Using this setup, detection of IgG from a whole blood sample in 100 s of application was demonstrated.…”

Section: Introductionmentioning

confidence: 99%